https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/trial-suggests-no-adverse-effects-vaginal-progesterone-prophylaxis-prevention-preterm-birth-child/
Trial suggests no adverse effects of vaginal progesterone prophylaxis for the prevention of preterm birth on child at age two
28 Jun 2016, 2:18 p.m.
Diagnostics and Imaging Theme Lead Professor Neil Sebire has teamed up with researchers from nine other establishments to carry out the largest randomised trial to investigate the long-term safety of vaginal progesterone prophylaxis for preterm births.
Research has shown reduced risk of preterm births in high risk women when progesterone is administered, however, there remains uncertainty over the long term effects on the child.
A randomised control trial was carried out in 1,228 women who were at increased risk of preterm birth. Women were randomly assigned to either progesterone capsules or placebos. Results showed that administration of progesterone did not significantly affect the risk of obstetric (foetal death or birth before 34 weeks), neonatal (including death, brain injury or bronchopulmonary dysplasia) or childhood outcomes (standardised cognitive score at two years of age).
Results showed progesterone use was not associated with preterm birth or adverse neonatal outcomes, as well as having no longer term effects at age of two. Findings have been published in the Lancet.
Professor Waseem Qasim named in list of leading global health leaders
Professor Waseem Qasim, Consultant at GOSH and Professor of Cell and Gene Therapy at University College London has been named in TIME magazine’s 2026 TIME100 Health List of the World’s Most Influential Leaders in Health.
Alyssa Tapley named in list of leading global health leaders
GOSH patient, Alyssa Tapley, 17 from Leicester, has been named in TIME’S 2026 TIME100 Health List of the World’s Most Influential Leaders in Health.
GOSH joins partnership to boost early diagnosis and deliver better treatments
GOSH is partnering with LifeArc to set up KidsRare - a new initiative to help deliver more tests and treatments for children living with a rare disease.
How linked health and education data is changing what we know about children with neurodisability
Children with neurodisability often have complex health and educational needs, but population level data on long term outcomes remains limited. New research from GOS-ICH addresses this gap using one of the largest national birth cohorts to date.